Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
The Yale Journal of Biology and Medicine · 2024
DOI: 10.59249/hwid7537 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Yale Journal of Biology and Medicine, 2024. Verfasst von Lamprini Banou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Genetic Therapy, Genetic Vectors, Eye Diseases. Die Arbeit wurde bisher 26-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Ocular gene therapy has rapidly advanced from proof-of-concept studies to clinical trials by exploiting the unique advantages of the eye, including its easy accessibility, relative immune privilege, and the ability to use the contralateral eye as a control. An important step forward was achieved with the Food and Drug Administration (FDA) approval of voretigene neparvovec (Luxturna) for the treatment of biallelic RPE65-mutation-associated retinal dystrophies in 2017. Gene therapy is a promising field aimed at treating various inherited and acquired eye diseases. Viral vectors such as adeno-associated virus (AAV) are mainly used to efficiently deliver genes. Despite the immune-privileged status of the eye, viral vector-based therapies can induce immune responses, potentially leading to gene therapy-associated uveitis. Future directions include developing strategies to reduce immune responses while maintaining therapeutic efficacy, optimizing vector selection, and improving delivery techniques. Continued advances in the field of viral vectors, particularly AAV, are expanding the potential applications of gene therapy to treat a variety of ocular diseases. To fully realize the potential of ocular gene therapy, more research and clinical trials are needed to improve these methods, ensure safe and efficient treatments, and ultimately overcome existing obstacles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Thessaly, Larissa, Greece.
- Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, USA.
Zitieren
APA
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024). Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions. The Yale Journal of Biology and Medicine. https://doi.org/10.59249/hwid7537
Vancouver
Banou L, Sarrafpour S, Teng CC, Liu J. Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions. The Yale Journal of Biology and Medicine. 2024. doi:10.59249/hwid7537
BibTeX
@article{Banou2024,
author = {Banou, Lamprini and Sarrafpour, Soshian and Teng, Christopher C and Liu, Ji},
title = {Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions},
journal = {The Yale Journal of Biology and Medicine},
year = {2024},
doi = {10.59249/hwid7537}
}
EUVIMED